CA2870293C - Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same - Google Patents

Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same Download PDF

Info

Publication number
CA2870293C
CA2870293C CA2870293A CA2870293A CA2870293C CA 2870293 C CA2870293 C CA 2870293C CA 2870293 A CA2870293 A CA 2870293A CA 2870293 A CA2870293 A CA 2870293A CA 2870293 C CA2870293 C CA 2870293C
Authority
CA
Canada
Prior art keywords
seq
fragment
consensus
acid sequence
signal peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2870293A
Other languages
English (en)
French (fr)
Other versions
CA2870293A1 (en
Inventor
David B. Weiner
Devon SHEDLOCK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Priority to CA3194125A priority Critical patent/CA3194125A1/en
Publication of CA2870293A1 publication Critical patent/CA2870293A1/en
Application granted granted Critical
Publication of CA2870293C publication Critical patent/CA2870293C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2870293A 2012-04-12 2013-04-12 Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same Active CA2870293C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3194125A CA3194125A1 (en) 2012-04-12 2013-04-12 Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623428P 2012-04-12 2012-04-12
US61/623,428 2012-04-12
PCT/US2013/036413 WO2013155441A1 (en) 2012-04-12 2013-04-12 Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3194125A Division CA3194125A1 (en) 2012-04-12 2013-04-12 Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

Publications (2)

Publication Number Publication Date
CA2870293A1 CA2870293A1 (en) 2013-10-17
CA2870293C true CA2870293C (en) 2023-05-09

Family

ID=49328209

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2870293A Active CA2870293C (en) 2012-04-12 2013-04-12 Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
CA3194125A Pending CA3194125A1 (en) 2012-04-12 2013-04-12 Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3194125A Pending CA3194125A1 (en) 2012-04-12 2013-04-12 Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

Country Status (9)

Country Link
US (5) US9597388B2 (member.php)
EP (2) EP2836230B1 (member.php)
JP (5) JP6389163B2 (member.php)
KR (5) KR102877352B1 (member.php)
CN (2) CN110051835A (member.php)
AU (1) AU2013245729B2 (member.php)
CA (2) CA2870293C (member.php)
IN (1) IN2014DN09351A (member.php)
WO (1) WO2013155441A1 (member.php)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN09351A (member.php) * 2012-04-12 2015-07-17 Univ Pennsylvania
AU2015221388A1 (en) * 2014-02-19 2016-08-04 Emergent Biosolutions Canada Inc. Methods of modulating an immune response
EP2944321A1 (en) * 2014-05-12 2015-11-18 Institut De Recherche Pour Le Développement (IRD) Immunogenic peptides of EBOLA and applications thereof
SG10201901735XA (en) * 2014-09-03 2019-03-28 Bavarian Nordic As Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
AP2017009822A0 (en) * 2014-09-03 2017-03-31 Bavarian Nordic As Methods and compositions for enhancing immune responses
EA035504B1 (ru) 2014-09-03 2020-06-25 Бавариан Нордик А/С Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
KR20250108761A (ko) * 2014-10-01 2025-07-15 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신
WO2016079572A1 (en) * 2014-11-21 2016-05-26 Wayengara Misaki Conserved b cell epitopes of filovirus glycoprotein and their use as either biomarkers or therapeutics and sub-unit vaccines for ebola virus and marburg virus
EP3233113A1 (en) * 2014-12-16 2017-10-25 CureVac AG Ebolavirus and marburgvirus vaccines
KR20170122750A (ko) * 2015-01-28 2017-11-06 인티그레이티드 바이오쎄라퓨틱스, 인크. 말 면역글로불린 조성물 및 필로바이러스 매개 질병을 치료하기 위한 용도
CN105582532A (zh) * 2015-08-30 2016-05-18 李小彦 可溶性埃博拉病毒包膜蛋白疫苗的制备方法及其用途
KR102678400B1 (ko) 2016-05-05 2024-06-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법
US20190185548A1 (en) * 2016-06-07 2019-06-20 Abivax Antiviral polyclonal antibodies against ebola virus and the uses thereof
US10925956B2 (en) 2016-07-15 2021-02-23 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
US11186626B2 (en) * 2016-10-11 2021-11-30 Integrated Biotherapeutics, Inc. Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop
EA201892124A1 (ru) * 2016-12-02 2019-04-30 Дэвид Б. Уэйнер Днк-конструкции антител и способы их применения
WO2018183443A1 (en) 2017-03-28 2018-10-04 Children's Hospital Medical Center Vlp-based monovalent ebola vaccines and methods of making and using same
WO2018185732A1 (en) 2017-04-06 2018-10-11 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
NL268156A (member.php) 1960-08-22
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
WO1993025673A1 (en) 1992-06-04 1993-12-23 The Regents Of The University Of California In vivo gene therapy with intron-free sequence of interest
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
ATE302854T1 (de) 1993-01-26 2005-09-15 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
TW499412B (en) 1996-11-26 2002-08-21 Dimensional Pharm Inc Aminoguanidines and alkoxyguanidines as protease inhibitors
US6200959B1 (en) * 1996-12-04 2001-03-13 Powerject Vaccines Inc. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
CA2285056C (en) 1997-04-03 2004-12-14 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
IL133710A0 (en) 1997-06-30 2001-04-30 Rhone Poulence Rorer S A Improved method for transferring nucleic acid into the striped muscle and combination thereof
CA2330211A1 (en) 1998-06-08 1999-12-16 Karel Petrak Formulations for electroporation
CA2337652C (en) 1998-07-13 2013-03-26 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
WO2002079239A2 (en) * 2001-01-31 2002-10-10 U.S. Army Medical Research Institute Of Infectious Diseases Chimeric filovirus glycoprotein
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
WO2003028632A2 (en) * 2001-10-01 2003-04-10 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Development of a preventive vaccine for filovirus infection in primates
US7211378B2 (en) 2002-01-31 2007-05-01 Wisconsin Alumni Research Foundation Filovirus vectors and noninfectious filovirus-based particles
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US20050255123A1 (en) * 2002-04-30 2005-11-17 The Trustees Of The University Of Pennsylvania Chimeric ebola virus envelopes and uses therefor
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
AU2003295366B2 (en) 2002-11-04 2011-11-24 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
TWI303275B (en) 2003-05-30 2008-11-21 Advisys Inc Devices and methods for biomaterial production
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
US8101739B2 (en) 2004-09-27 2012-01-24 The United States Of America As Represented By The Department Of Health And Human Services Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector
BRPI0707106B1 (pt) * 2006-01-13 2022-06-07 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Polinucleotídeo interleucina-15, vetor de expressão, e, composição farmacêutica
AU2008352966C1 (en) 2007-12-18 2014-09-25 Boston Medical Center Corporation Pre- or post-exposure treatment for filovirus or arenavirus infection
EP2265715B1 (en) * 2008-04-04 2016-12-28 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same
CA2725383C (en) 2008-05-28 2018-09-25 Ruxandra Draghia-Akli Smallpox dna vaccine and the antigens therein that elicit an immune response
WO2010057159A2 (en) * 2008-11-17 2010-05-20 Vgx Pharmaceuticals, Llc Antigens that elicit immune response against flavivirus and methods of using same
NZ602322A (en) 2008-11-21 2013-12-20 Bavarian Nordic As Vector comprising multiple homologous nucleotide sequences
EP2473525A4 (en) * 2009-09-02 2013-08-21 Us Army MONOCLONAL ANTIBODIES AGAINST GLYCOPROTEIN OF EBOLA SUDAN BONIFACE VIRUS
US8956865B2 (en) 2010-08-11 2015-02-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of growing an embryo to a blastocyst stage of development
EP2632484B1 (en) * 2010-10-28 2018-02-28 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Filovirus fusion proteins and their uses
US10849975B2 (en) * 2011-02-03 2020-12-01 Thomas Jefferson University Multivalent vaccines for rabies virus and filoviruses
IN2014DN09351A (member.php) 2012-04-12 2015-07-17 Univ Pennsylvania
GB2504774A (en) 2012-08-10 2014-02-12 Munster Simms Eng Ltd Diaphragm pump with integral motor housing and rear pump housing
TWI548337B (zh) 2015-10-16 2016-09-01 技嘉科技股份有限公司 散熱模組、顯示卡組件及電子裝置

Also Published As

Publication number Publication date
JP2015527297A (ja) 2015-09-17
EP4190350A1 (en) 2023-06-07
JP2022078289A (ja) 2022-05-24
KR20220012403A (ko) 2022-02-03
US20200390880A1 (en) 2020-12-17
KR102146904B1 (ko) 2020-08-24
KR20200104917A (ko) 2020-09-04
KR102351881B1 (ko) 2022-01-18
US10765733B2 (en) 2020-09-08
CN104884083A (zh) 2015-09-02
AU2013245729A1 (en) 2014-10-30
US20150335726A1 (en) 2015-11-26
US11723969B2 (en) 2023-08-15
CA2870293A1 (en) 2013-10-17
JP2025020200A (ja) 2025-02-12
KR20240010758A (ko) 2024-01-24
KR102877352B1 (ko) 2025-10-29
IN2014DN09351A (member.php) 2015-07-17
EP2836230A4 (en) 2016-03-02
EP2836230B1 (en) 2022-09-07
JP6389163B2 (ja) 2018-09-12
WO2013155441A1 (en) 2013-10-17
JP7164353B2 (ja) 2022-11-01
KR20250156204A (ko) 2025-10-31
US20170165350A1 (en) 2017-06-15
JP2021001191A (ja) 2021-01-07
US10034930B2 (en) 2018-07-31
US20240100143A1 (en) 2024-03-28
US9597388B2 (en) 2017-03-21
AU2013245729B2 (en) 2016-09-29
CA3194125A1 (en) 2013-10-17
JP2019006787A (ja) 2019-01-17
KR20140146652A (ko) 2014-12-26
EP2836230A1 (en) 2015-02-18
US20180344840A1 (en) 2018-12-06
CN110051835A (zh) 2019-07-26

Similar Documents

Publication Publication Date Title
US11723969B2 (en) Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
US12240872B2 (en) Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
EA045714B1 (ru) Консенсусные антигены филовируса, конструкции нуклеиновых кислот и вакцины, полученные на их основе, и способы их применения

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180323

EEER Examination request

Effective date: 20180323

EEER Examination request

Effective date: 20180323

EEER Examination request

Effective date: 20180323

EEER Examination request

Effective date: 20180323

EEER Examination request

Effective date: 20180323